Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26346559 | 0.87 | SLC6A3 (0.43) | PTGS2SLC6A3PTGS1SLC6A2BCL2L1 | |
| SCHEMBL19839395 | 0.85 | SLC6A3 (0.64) | PTGS2SLC6A3PTGS1SLC6A2 | |
| SCHEMBL2484636 | 0.82 | PTGS2 (0.47) | PTGS2SLC6A3PTGS1SLC6A2ALDH1A1 | |
| SCHEMBL15539939 | 0.74 | SLC6A3 (0.64) | SLC6A3SLC6A2 | |
| SCHEMBL25487624 | 0.74 | PTGS2 (0.42) | PTGS2SLC6A3PTGS1SLC6A2 | |
| SCHEMBL24165528 | 0.74 | PTGS2 (0.42) | PTGS2SLC6A3PTGS1SLC6A2ALDH1A1 | |
| SCHEMBL24261125 | 0.74 | PTGS2 (0.42) | PTGS2SLC6A3PTGS1SLC6A2MEN1 | |
| SCHEMBL19839271 | 0.74 | PTGS2 (0.39) | PTGS2SLC6A3PTGS1SLC6A2BCL2L1 | |
| SCHEMBL19839945 | 0.72 | SLC6A3 (0.58) | PTGS2SLC6A3PTGS1SLC6A2 | |
| SCHEMBL19839299 | 0.72 | PTGS2 (0.40) | PTGS2SLC6A3PTGS1SLC6A2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159524-A1 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159524-A1 | METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | CTPS2, CDK2, PAICS | PTGS2 352/4885SLC6A3 1324/4885PTGS1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.